P. Baverel

发表

Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

P. Sharma, L. Dirix, B. Keam, 2019, Clinical Cancer Research.

Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma

A. Gupta, B. Wang, L. Roskos, 2018, Clinical pharmacology and therapeutics.

A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.

R. Faggioni, E. Piper, D. She, 2017, Drug metabolism and pharmacokinetics.

Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

P. Vicini, M. Taboada, Nancy Lee, 2019, Clinical and translational science.

Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial

F. Mercier, Jiawen Zhu, A. Sostelly, 2022, Contemporary clinical trials communications.

Dose‐Exposure‐Response Relationship of the Investigational Anti‐Interleukin‐13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

P. Vicini, M. Karlsson, B. Agoram, 2018, Clinical pharmacology and therapeutics.

Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point.

J. Smith, A. Woodcock, P. H. van der Graaf, 2013, The Journal of allergy and clinical immunology.

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

L. Roskos, I. González-García, Xiang Guo, 2021, Oncoimmunology.

A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development

P. Bonate, D. Yin, D. Bottino, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy

Helen Moore, I. González-García, S. Spencer, 2021, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total

P. Vicini, J. Hood, I. González-García, 2021, Pharmaceutics.

Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status

A. Gupta, P. Vicini, P. Dennis, 2018, Clinical pharmacology and therapeutics.

Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.

T. Powles, A. Gupta, P. Dennis, 2017 .

Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol

B. Ribba, R. Peck, Dominic Stefan Bräm, 2022, CPT: pharmacometrics & systems pharmacology.

Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models

Mats O. Karlsson, Radojka M. Savic, Paul G. Baverel, 2011, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.

P. Kuna, B. Agoram, E. Piper, 2015, British journal of clinical pharmacology.

Evaluation of the nonparametric estimation method in nonmem VI: application to real data

Mats O. Karlsson, Radojka M. Savic, Justin J. Wilkins, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models

P. Vicini, G. Lythe, J. Yates, 2021, CPT: pharmacometrics & systems pharmacology.

Population pharmacokinetics of durvalumab and fixed dosing regimens in patients with advanced solid tumors.

A. Gupta, P. Dennis, L. Roskos, 2017 .